[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Hori J, Kato Y, Kitahara K, Tokumitsu M, Saga Y, Hashimoto H, Kaneko S, Yachiku S: [A case of late recurrence of germ cell tumor]. Nihon Hinyokika Gakkai Zasshi; 2004 Jul;95(5):729-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He underwent chemotherapy followed by retroperitoneal lymph node dissection and pathologic examination revealed mostly necrotic tissue with a small amount of teratomatous tissue.
  • Two years later, a hyper echoic lesion was found in the left testis, and left high orchiectomy was performed.
  • The resected specimen appeared to be a burned-out testicular tumor.
  • Pathologic examination revealed well-differentiated adenocarcinoma.
  • Since no primary adenocarcinoma was found, this case was considered late relapse of a germ cell tumor.
  • [MeSH-major] Adenocarcinoma / secondary. Germinoma / secondary. Lung Neoplasms / secondary. Retroperitoneal Neoplasms / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Combined Modality Therapy. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Male. Orchiectomy. Time Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15354721.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


2. Ferri E, Azzolini N, Sebastio N, Salsi P, Meli S, Cortellini P: [Unusual case of mesothelioma of the tunica vaginalis associated with prostatic adenocarcinoma]. Minerva Urol Nefrol; 2000 Mar;52(1):33-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual case of mesothelioma of the tunica vaginalis associated with prostatic adenocarcinoma].
  • [Transliterated title] Raro caso di mesotelioma della vaginale del testicolo associato ad adenocarcinoma della prostata.
  • Malignant mesothelioma of the tunica vaginalis testis, is a very rare neoplasm with highly aggressive biological behaviour.
  • A testicular mass is always observed, often accompanied with hydrocele.
  • The response to chemotherapy and radiotherapy is poor.
  • The median survival, without surgical treatment is 23 months.
  • A rare case of malignant mesothelioma of the tunica vaginalis testis, observed in a patient affected by prostate neoplasm is reported.
  • Rectal ultrasonography and biopsy showed an adenocarcinoma at T1c clinical stage.
  • A radical prostatectomy was carried out and histology showed an adenocarcinoma, Gleason score 7 pT3bN0M0.
  • Surgery was followed by radiation therapy.
  • After three years, a pleural seroma, a cutaneous mass and testicular nodule were observed and cytological examination showed endothelial cells.
  • Cytological examination confirmed malignant mesothelioma of the tunica vaginalis testis.
  • The therapeutic options for this aggressive neoplasm are discussed.
  • Since chemotherapy and radiation therapy had poor results, a rapid surgical treatment, by radical orchiectomy, is important.
  • [MeSH-major] Adenocarcinoma / surgery. Mesothelioma / surgery. Neoplasms, Second Primary / surgery. Prostatic Neoplasms / surgery. Testicular Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11517828.001).
  • [ISSN] 0393-2249
  • [Journal-full-title] Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • [ISO-abbreviation] Minerva Urol Nefrol
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


3. Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ: Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol; 2002 Aug;168(2):542-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: High-dose (400 mg.) oral ketoconazole 3 times daily with replacement doses of hydrocortisone has become a standard treatment option for patients with advanced prostate cancer which progresses after androgen deprivation.
  • However, toxicity can hinder the ability to deliver treatment and the cost of the regimen can be substantial.
  • Therefore, a prospective phase II study was conducted to assess the efficacy and safety of a regimen of low dose (200 mg.) oral ketoconazole 3 times daily with replacement doses of hydrocortisone in men with androgen independent prostate cancer.
  • MATERIALS AND METHODS: The study included 28 patients with progressive prostate cancer despite anorchid levels of testosterone and ongoing testicular androgen suppression.
  • Treatment consisted of low dose ketoconazole and replacement doses of oral hydrocortisone (20 mg. every morning and 10 mg. at bedtime).
  • At the time of disease progression patients were treated with high dose ketoconazole and continued on the same dose of hydrocortisone.
  • In general, therapy was well tolerated.
  • Of the 16 patients who received high dose ketoconazole after disease progression with low dose ketoconazole, 3 were removed from treatment due to toxicity and no patient responded to high dose ketoconazole.
  • There was no difference in the distribution of pretreatment endocrine values between responders and nonresponders, and the magnitude of change in adrenal androgen levels was not associated with response to therapy, although a potential association could easily have been missed due to small sample size.
  • [MeSH-major] Hydrocortisone / administration & dosage. Ketoconazole / administration & dosage. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Aged. Aged, 80 and over. Androgen Antagonists / administration & dosage. Androgens / blood. Biomarkers, Tumor / blood. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Humans. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / blood. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12131305.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Androgens; 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen; R9400W927I / Ketoconazole; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


Advertisement
4. Gunlusoy B, Arslan M, Selek E, Cetinel M, Ayder AR, Cicek S: A case report: Prostatic carcinoma with metastasis to the testicle. Int Urol Nephrol; 2004;36(1):63-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secondary testicular tumours are rare.
  • We present a 54 years old patient with testicular metastasis from carcinoma of the prostate with a 7 years history of hormonotherapy and chemotherapy for advanced carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms / pathology. Testicular Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Dec;164(6):2026 [11061911.001]
  • [Cites] Br J Urol. 1990 Aug;66(2):205-7 [2390707.001]
  • (PMID = 15338677.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


5. Lutke Holzik MF, Hoekstra HJ, Mulder NH, Suurmeijer AJ, Sleijfer DT, Gietema JA: Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor. Ann Surg Oncol; 2003 Mar;10(2):131-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor.
  • BACKGROUND: After chemotherapy for nonseminomatous testicular germ cell tumor (NSTGCT), residual masses or recurrent disease may contain a non-germ cell malignancy (NGCM).
  • RESULTS: Nine patients developed an NGCM.
  • Four patients had an NGCM in the resected residual tumor mass after chemotherapy: three patients had a sarcoma, and one patient had both a sarcoma and an adenocarcinoma.
  • Five patients developed a late recurrence with an NGCM after 39, 40, 72, 72, and 84 months.
  • One patient had a primitive neuroectodermal tumor, one had a sarcoma, and three had an adenocarcinoma in the resected recurrent tumor mass.
  • CONCLUSIONS: Sarcoma, adenocarcinoma, or both in residual or recurrent tumor masses after combined-modality NSTGCT treatment are rare.
  • Complete surgical resection of the tumor mass is the only curative treatment option.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Neoplasms, Germ Cell and Embryonal / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adult. Cisplatin / administration & dosage. Humans. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiography. Neoplasm, Residual / pathology. Neoplasm, Residual / radiography. Sarcoma / pathology. Sarcoma / radiography. Survival Rate. Teratoma / pathology. Teratoma / radiography. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Surg Oncol. 2003 Mar;10(2):100-1 [12620901.001]
  • (PMID = 12620907.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Game X, Houlgatte A, Fournier R, Duhamel P, Baranger B, Khoury S: [Dedifferentiation of mature teratomas secondary to testicular cancer: report of 2 cases]. Prog Urol; 2001 Feb;11(1):73-6; discussion 76-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dedifferentiation of mature teratomas secondary to testicular cancer: report of 2 cases].
  • [Transliterated title] Dédifférenciation des tératomes matures secondaires à un cancer du testicule: à propos de deux cas.
  • However, PET scan suggests the diagnosis of malignant teratoma in the presence of increased uptake by the lesion.
  • Treatment consists of complete resection of the tumour mass.
  • The possibility of long-term malignant dedifferentiation of a teratoma therefore requires prolonged and regular life-long surveillance of patients presenting a mature teratoma after chemotherapy for non-seminomatous germ cell tumour of the testis.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Transformation, Neoplastic / pathology. Neoplasms, Second Primary / pathology. Retroperitoneal Neoplasms / pathology. Teratoma / pathology. Testicular Neoplasms / surgery

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11296651.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Pedraza R, Kwart AM: Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression? Urology; 2003 Apr;61(4):770-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
  • OBJECTIVES: To determine the hormonal (luteinizing hormone [LH], testosterone) and biochemical (prostate-specific antigen [PSA]) response to withdrawal of LH-releasing hormone (LHRH) agonist therapy for patients with prostate cancer with an undetectable PSA who received this treatment for an extended period.
  • METHODS: Four selected patients older than 70 years of age with advanced adenocarcinoma of the prostate who were treated with a depot injection of LHRH and antiandrogen therapy had their treatment discontinued.
  • RESULTS: At the time androgen ablative therapy was discontinued, patients had received LHRH agonist/antiandrogen therapy for a mean of 108 months (range 94 to 120).
  • CONCLUSIONS: Withdrawing hormonal therapy in asymptomatic patients with advanced prostate cancer after prolonged total androgen blockade was noted to be safe and effective in elderly patients who had achieved an undetectable PSA level.
  • It appears that reduced testosterone levels may be a result of altered and potentially irreversible Leydig cell function rather than continued suppression of the hypothalamic-pituitary-testicular axis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / administration & dosage. Antineoplastic Agents, Hormonal / therapeutic use. Gonadotropin-Releasing Hormone / administration & dosage. Gonadotropin-Releasing Hormone / agonists. Luteinizing Hormone / blood. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy. Testosterone / blood
  • [MeSH-minor] Aged. Delayed-Action Preparations. Drug Administration Schedule. Follow-Up Studies. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12670563.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Delayed-Action Preparations; 33515-09-2 / Gonadotropin-Releasing Hormone; 3XMK78S47O / Testosterone; 9002-67-9 / Luteinizing Hormone; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


8. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM: Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol; 2008 Nov-Dec;26(6):595-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of testicular teratoma: a chemoresistant phenotype.
  • RESULTS: Two patients presented with clinical stage I disease in which malignant transformation occurred within the primary testis tumor (rhabdomyosarcoma in 1 and adenocarcinoma in 1).
  • Of the remaining 7 patients, the clinical stages were IIA (N = 1), IIB (N = 3), and III (N = 3), and all were treated with chemotherapy followed by RPLND.
  • The MTT histology of these RPLND specimens consisted of adenocarcinoma (N = 3), rhabdomyosarcoma (N = 2), angiosarcoma (N = 1), and astrocytoma (N = 1).
  • Following preoperative chemotherapy, a significant radiologic response (defined as more than a 25% reduction in maximum tumor circumferential diameter) was demonstrated in 1 patient, and normalization of serum tumor markers was demonstrated in 6.
  • CONCLUSIONS: In our experience, MTT is significantly resistant to current chemotherapeutic regimens, as demonstrated by its poor radiologic response to treatment.
  • Alternative therapeutic strategies targeted to MTT are thus needed.
  • [MeSH-major] Teratoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Drug Resistance, Neoplasm. Humans. Lymph Node Excision. Male. Neoplasm Staging. Retroperitoneal Space

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2781-8 [15837993.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1998 Jun;89(6):622-6 [9666691.001]
  • [Cites] Semin Urol Oncol. 1998 May;16(2):65-71 [9649229.001]
  • [Cites] J Urol. 1998 Mar;159(3):859-63 [9474169.001]
  • [Cites] Scand J Urol Nephrol. 2003;37(2):177-8 [12745729.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):860-3 [2990657.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4285-91 [14645417.001]
  • [Cites] J Urol. 1998 Jan;159(1):133-8 [9400455.001]
  • [CommentIn] Urol Oncol. 2009 Mar-Apr;27(2):218; author reply 218-9 [19285238.001]
  • (PMID = 18367105.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS610854; NLM/ PMC4121060
  •  go-up   go-down


9. Sheski FD, Henley JD, Foster RS, Einhorn LH: Prostate carcinoma presenting as multiple pulmonary nodules in an asymptomatic patient with a history of testicular nonseminomatous germ cell tumor. Urology; 2003 Oct;62(4):748
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate carcinoma presenting as multiple pulmonary nodules in an asymptomatic patient with a history of testicular nonseminomatous germ cell tumor.
  • We report such a patient, who responded to combination androgen blockade therapy.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / secondary. Neoplasms, Germ Cell and Embryonal. Neoplasms, Second Primary. Prostatic Neoplasms / pathology. Testicular Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Flutamide / administration & dosage. Humans. Leuprolide / administration & dosage. Male. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / surgery. Orchiectomy. Postoperative Complications


10. Hagiuda J, Matsumoto M, Hanawa Y, Ishikawa H, Marumo K: [Adenocarcinoma of the rete testis. A case report]. Nihon Hinyokika Gakkai Zasshi; 2010 Nov;101(7):749-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma of the rete testis. A case report].
  • Adenocarcinoma of the rete testis is a rare malignant tumor with a poor prognosis.
  • About 60 cases of this adenocarcinoma have been reported in the literature.
  • The diagnosis is often difficult and made incidentally.
  • Herein, we report a case of adenocarcinoma of the rete testis and review the literature.
  • Magnetic resonance imaging (MRI) showed a left hydrocele with central necrosis of the testis.
  • Positron emission tomography (PET) was performed in another hospital, and the patient was referred for a left testicular tumor, multiple lung metastases, and para-aorta lymph node metastasis.
  • Pathological examination revealed a hard whitish mass around the testis involving the epididymis and tunica vaginalis and spreading under the subcutaneous tissue.
  • Histological examination revealed adenocarcinoma in the hilum of the testis, which extended to the subcutaneous tissue but not to the surface of the scrotum.
  • The tunica albuginea was intact, and no invasion of carcinoma in the testis was seen.
  • After the histological diagnosis of adenocarcinoma of the rete testis was confirmed, computed tomography (CT) was performed and showed multiple pulmonary nodules and para-aortica lymph node swelling of 3 cm diameter.
  • Because the patient did not wish to receive chemotherapy or other aggressive treatment, he has been followed-up with palliative care since his diagnosis.
  • Although local recurrence has occurred 4 months later, he is still alive for 8 months since his diagnosis.
  • [MeSH-major] Adenocarcinoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Aged, 80 and over. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Orchiectomy. Palliative Care. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21174741.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Fleckenstein GH, Gunawan B, Brinck U, Wuttke W, Emons G: Simultaneous sertoli cell tumor and adenocarcinoma of the tunica vaginalis testis in a patient with testicular feminization. Gynecol Oncol; 2002 Mar;84(3):460-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous sertoli cell tumor and adenocarcinoma of the tunica vaginalis testis in a patient with testicular feminization.
  • BACKGROUND: The association of testicular feminization with late diagnosis in a patient with a large Sertoli cell tumor and a metastasizing adenocarcinoma of the tunica vaginalis testis is unusual.
  • CASE: Testicular feminization was diagnosed in a 72-year-old patient, who was admitted with a large lower abdominal mass.
  • Histologically, we found a well-differentiated Sertoli cell tumor and an adenocarcinoma of the tunica vaginalis testis with metastases in the sigmoid colon, rectum, and omentum.
  • After debulking surgery to optimal residual disease and four courses of chemotherapy (cisplatin and etoposide), there was no evidence of disease (clinically) for 24 months before an intraabdominal and inguinal relapse occurred.
  • Due to the unwillingness of the patient to receive salvage chemotherapy or palliative abdominal surgery, the disease progressed rapidly and she died 27 months after the initial operation.
  • CONCLUSION: This is the first reported case of an advanced carcinoma of the tunica vaginalis testis occurring simultaneously with a large Sertoli cell tumor in a patient with testicular feminization.
  • Surgical debulking and platinum-based chemotherapy rendered the patient clinically free of disease for 2 years.
  • [MeSH-major] Adenocarcinoma / pathology. Androgen-Insensitivity Syndrome / pathology. Sertoli Cell Tumor / pathology. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Testicular Feminization.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11855889.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Stewart AK, Bland KI, McGinnis LS Jr, Morrow M, Eyre HJ: Clinical highlights from the National Cancer Data Base, 2000. CA Cancer J Clin; 2000 May-Jun;50(3):171-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The NCDB collects oncology patient demographic information, diagnostic and treatment information, and outcomes data from a broad spectrum of hospital-based cancer registries throughout the US, ranging from large research and teaching facilities to small community hospitals.
  • Included among these are articles on breast cancer, gastric carcinoma, head and neck cancers, leukemia, liver carcinoma, lung cancer, parathyroid tumors, prostate carcinoma, small bowel adenocarcinoma, testicular malignancies, and vulvar melanoma.
  • The NCDB has accrued more than 6.4 million cancer cases for this time period.
  • Sufficient numbers of rare cancers are reported to the NCDB to permit some types of clinical evaluation not possible using other data sources.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / epidemiology. Female. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / therapy. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Liver Neoplasms / epidemiology. Liver Neoplasms / therapy. Lung Neoplasms / epidemiology. Lung Neoplasms / therapy. Male. Middle Aged. Parathyroid Neoplasms / epidemiology. Parathyroid Neoplasms / therapy. Stomach Neoplasms / epidemiology. Survival Rate. Testicular Neoplasms / epidemiology. Testicular Neoplasms / therapy. United States / epidemiology. Vulvar Neoplasms / epidemiology. Vulvar Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10901740.001).
  • [ISSN] 0007-9235
  • [Journal-full-title] CA: a cancer journal for clinicians
  • [ISO-abbreviation] CA Cancer J Clin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


15. Ray-Coquard I, Pautier P, Pujade-Lauraine E, Méeus P, Morice P, Treilleux I, Duvillard P, Alexandre J, Lhommé C, Selle F, Guastalla J: [Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France]. Bull Cancer; 2010 Jan;97(1):123-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France].
  • [Transliterated title] Les tumeurs rares de l'ovaire: stratégies thérapeutiques en 2010, Observatoire francophone des tumeurs rares de l'ovaire et émergence des centres de références.
  • Tumors of the stromal (Leydig cells) and/or sex cords (Sertoli cells) represent approximately 7% of ovarian cancers and develop from the conjunctive tissue (respectively, interstitial and nurse cells) of the ovaries.
  • Treatment of rare ovarian tumors is currently as follows.
  • Surgery is the same as that for ovarian adenocarcinoma, with one major difference: conservation of reproductive function in women of reproductive age is usual case for this type of tumor.
  • Chemotherapy for germ cell and sex cords tumors, based on data reported in the literature is the same as that prescribed for testicular germ-cell tumors.
  • Surgery, chemotherapy and possible surgical intervention for residual lesions are highly complex.
  • Too rare to be included in randomized studies, treatment of these tumors has benefited from the therapeutic advancements made against testicular germ-cell tumors or with publications using retrospective data.
  • Because of the rarity of these tumours a specialized website (www.ovaire-rare.org) was developed in France in 2002.
  • [MeSH-major] Cancer Care Facilities / organization & administration. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / therapy. Adult. Antineoplastic Agents / therapeutic use. Female. France. Humans. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / therapy. Rare Diseases / pathology. Rare Diseases / therapy. Sarcoma / pathology. Sarcoma / therapy. Sex Cord-Gonadal Stromal Tumors / pathology. Sex Cord-Gonadal Stromal Tumors / therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20007069.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Chmiel B, Nocoń G: [Secondary primary, bilocal sigmoid colon adenocarcinoma in a patient previously treated for testicular cancer]. Wiad Lek; 2004;57(5-6):288-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Secondary primary, bilocal sigmoid colon adenocarcinoma in a patient previously treated for testicular cancer].
  • Frequency of neoplastic diseases among patients cured successfully from testicular cancer is higher than in normal population.
  • The case of simultaneous adenocarcinoma of ascending and sigmoid colon in a man effectively treated before for testicular cancer is presented.
  • This case is an illustration of the problem of cancerogenesis within polyps of the large bowel in patients treated before by chemotherapy because of testicular cancer.
  • [MeSH-major] Adenocarcinoma. Neoplasms, Second Primary. Rectal Neoplasms. Sigmoid Neoplasms. Testicular Neoplasms
  • [MeSH-minor] Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15518079.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


17. Waguri N, Furukawa K, Shobugawa K, Takizawa K, Ikeda H, Iwamoto Y, Aiba T, Yoneyama O, Igarashi K, Tsukioka S, Yabe M, Kuwabara S, Shibuya H: [A case of gastric cancer with abdominal wall invasion treated by weekly low-dose paclitaxel therapy]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with abdominal wall invasion treated by weekly low-dose paclitaxel therapy].
  • Here we report a case of gastric cancer with diffuse abdominal wall invasion treated with weekly low-dose paclitaxel therapy.
  • A 62-year-old male visited our hospital because of abdominal distention, prepubic tumor,and testicular hydrocele.
  • Computed tomography revealed diffuse swelling of the abdominal wall and hydronephrosis of the right kidney.
  • Upper gastrointestinal endoscopy demonstrated type 3' advanced gastric cancer.
  • Pathological diagnosis of both gastric tumor and abdominal wall biopsy specimens was poorly-differentiated adenocarcinoma containing signet ring cell carcinoma.
  • Abdominal wall swelling like cuirass disappeared after 2 courses of low-dose paclitaxel therapy.
  • [MeSH-major] Abdominal Wall / pathology. Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Signet Ring Cell / pathology. Drug Administration Schedule. Humans. Male. Middle Aged. Neoplasm Invasiveness. Radiography, Abdominal. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912538.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. Willis SF, Winkler M, Savage P, Seckl MJ, Christmas TJ: Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour. BJU Int; 2007 Oct;100(4):809-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
  • OBJECTIVES: To examine the operative findings, histopathology and clinical outcome of patients undergoing repeat retroperitoneal lymph node dissection (RPLND) after initial chemotherapy and RPLND (PC-RPLND) for metastatic testicular germ cell tumour (GCT), as a small proportion relapse or have residual disease after incomplete resection in the lung, retrocrural or pelvic nodes, and retroperitoneum.
  • RESULTS: The median (range) time from original to repeat surgery was 2.4 (0.25-26.5) years, and the median follow-up after the repeat procedure was 5.8 (0.08-12.9) years.
  • There was no difference in survival between patients requiring only one PC-RPLND and those having a repeat procedure (P = 0.592).
  • The most common pathological findings in the repeat PC-RPLNDs were differentiated teratoma (19, 35%), malignant teratoma undifferentiated (nine, 17%), adenocarcinoma (eight, 15%) and necrotic tissue (five, 9.2%).
  • However, to avoid cancer recurrence and reoperation, it is crucial that the first PC-RPLND is careful and complete, preferably done in a centre with expertise in this procedure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymph Node Excision. Neoplasms, Germ Cell and Embryonal / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm, Residual. Prognosis. Reoperation. Retroperitoneal Space. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711512.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Morgan K, Srinivas S, Freiha F: Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis. Urology; 2004 Oct;64(4):808-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis.
  • Primary tumors known to metastasize to the testis, in order of decreasing frequency, are prostate, lung, gastrointestinal tract, melanoma, and kidney tumors.
  • Metastasis from bladder cancer to the testis is extremely rare, occurs with advanced and metastatic disease, and is usually a finding at autopsy.
  • We report a rare, and probably the first, case of solitary and synchronous metastatic transitional cell carcinoma of the bladder to the testis, discovered on the preoperative workup.
  • An incidentally discovered testicular mass in a man with high-grade, invasive bladder cancer should be considered a metastatic lesion until proven otherwise.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Deoxycytidine / analogs & derivatives. Testicular Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cystectomy. Cystitis / complications. Cystitis / diagnosis. Hematuria / etiology. Humans. Incidental Findings. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary. Orchiectomy. Positron-Emission Tomography. Prostatectomy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / secondary. Radiation Injuries / complications. Radiation Injuries / diagnosis. Transurethral Resection of Prostate. Urinary Diversion


20. Goldner B, Milosević Z, Sadiković S, Stojanović M: [Clinical and radiological manifestations of paraneoplastic syndrome of bronchogenic carcinoma]. Srp Arh Celok Lek; 2005 May-Jun;133(5-6):248-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to present some clinical and radiological manifestations of PNS in relation to bronchogenic carcinoma (BC) and to evaluate the usefulness of imaging findings in the diagnosis of asymptomatic BC.
  • Endocrine manifestations included: inappropriate antidiuretic hormone production syndrome (small-cell carcinoma), a gonadotropin effect with gynaecomastia and testicular atrophy (planocellular carcinoma, small-cell carcinoma), a case of Cushing Syndrome (small-cell carcinoma), and hypercalcaemia, due to the production of the parathyroid hormone-related peptide, which was associated with planocellular carcinoma.
  • A rare case of bilateral exophthalmos was found as PNS at adenocarcinoma.
  • Digital clubbing and hypertrophic osteoarthropathy (HO) were associated with planocellular and adenocarcinoma, while clubbing was much more common than HO, especially among women.
  • The differences between the two groups were related to the time of PNS appearance.
  • In the first group, PNS occurred late on in the illness, while in the second group, PNS preceded the diagnosis of BC.
  • Alternatively, the disappearance of a clinical or a radiological manifestation of PNS after surgery or chemotherapy may be an indicator of an improvement in health or PNS may be the first sign of illness recurrence.
  • [MeSH-major] Carcinoma, Bronchogenic / complications. Lung Neoplasms / complications. Paraneoplastic Syndromes / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16392281.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


21. Venkitaraman R, George M, Weerasooriya S, Selva-Nayagam S: Late solitary testicular metastasis from rectal cancer. J Cancer Res Ther; 2010 Jan-Mar;6(1):89-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late solitary testicular metastasis from rectal cancer.
  • Isolated testicular metastasis from rectal cancer is rare.
  • We describe the case of a patient who presented with a locally advanced rectal malignancy and underwent multimodality treatment with low anterior resection, postoperative radiotherapy and adjuvant chemotherapy.
  • He developed a painless testicular nodule while on follow-up, five years after the diagnosis of primary rectal cancer.
  • Histopathology and immunohistochemistry of orchidectomy specimen were compatible with a metastatic adenocarcinoma of rectal origin.
  • We hypothesize that this phenomenon of isolated relapse in a sanctuary site could be due to the altered biology and pattern of metastasis as a result of effective adjuvant systemic chemotherapy.
  • Treatment of late isolated relapse in the testis needs to be ascertained.
  • [MeSH-major] Adenocarcinoma / secondary. Rectal Neoplasms / pathology. Testicular Neoplasms / secondary
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Digestive System Surgical Procedures. Fluorouracil / therapeutic use. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479555.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Akin Takmaz S, Inan N, Günal S, Kaymak C, Sakalli M, Dikmen B: Ketamine combined with morphine for the management of cancer pain in a patient with meperidine tolerance and addiction. Agri; 2005 Jul;17(3):44-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pain treatment of patients with opioid addiction and tolerance may be challenging due to their unexpectedly higher pain sensitivities and opioid requirements.
  • Recently enhancement of morphine induced analgesia by low dose ketamine addition to the treatment regimen has been reported.
  • [MeSH-major] Analgesics / administration & dosage. Ketamine / administration & dosage. Morphine / administration & dosage. Pain, Intractable / drug therapy
  • [MeSH-minor] Adenocarcinoma / secondary. Adult. Drug Therapy, Combination. Drug Tolerance. Humans. Male. Meperidine. Neoplasm Metastasis. Spinal Neoplasms / secondary. Testicular Neoplasms / pathology

  • Hazardous Substances Data Bank. MORPHINE .
  • Hazardous Substances Data Bank. MEPERIDINE .
  • Hazardous Substances Data Bank. KETAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158342.001).
  • [ISSN] 1300-0012
  • [Journal-full-title] Aǧrı : Ağrı (Algoloji) Derneği'nin Yayın organıdır = The journal of the Turkish Society of Algology
  • [ISO-abbreviation] Agri
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Analgesics; 690G0D6V8H / Ketamine; 76I7G6D29C / Morphine; 9E338QE28F / Meperidine
  •  go-up   go-down


23. Tomaszewski JJ, Smaldone MC, Benoit RM: Inguinal canal recurrence of colorectal adenocarcinoma following cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Can J Urol; 2008 Dec;15(6):4428-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inguinal canal recurrence of colorectal adenocarcinoma following cytoreductive surgery and intraperitoneal hyperthermic chemotherapy.
  • Peritoneal carcinomatosis, the second most common cause of death among patients with colorectal carcinoma, may be managed with cytoreductive surgery and adjuvant intraoperative peritoneal hyperthermic chemotherapy (IHPC).
  • We present the case of a 35-year-old male with locally recurrent colorectal adenocarcinoma in the inguinal canal and testis following intraperitoneal debulking and IPHC.
  • When communicating with the peritoneal cavity, the inguinal canal may act as an anatomic sanctuary site and allow peritoneal carcinomatosis to escape the effects of intraperitoneal chemotherapy.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / therapy. Colorectal Neoplasms / therapy. Hyperthermia, Induced. Inguinal Canal / radionuclide imaging. Neoplasms, Second Primary / radionuclide imaging. Testicular Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046498.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


24. André T, Wislez M, Goncalves A, de La Motte Rouge T, Blay JY, Massard C, Bay JO, comité de rédaction du Bulletin du Cancer: [Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer]. Bull Cancer; 2010 Dec;97(12):1551-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Suite aux communications faites au congrès de l'American Society of Clinical Oncology 2010, qu'est ce qui va changer nos pratiques ? Le point de vue du comité de rédaction du Bulletin du cancer.
  • Best understanding of biological mechanisms and new molecules to inhibit targets allow in certain case, to use therapeutic targeting in the true sense.
  • The identification of the gene of fusion EML4-ALK in lung adenocarcinoma, and its inhibition by the crizotinib, constitute a considerable progress for 5% of patients with this disease.
  • In Advanced non-small cell lung cancer, myeloma and advanced lymphoma, maintenance therapy by monoclonal anti-body or inhibitors of tyrosines kinases showed the proof of their effectiveness.
  • In metastatic adenocarcinoma of the pancreas, there is finally an alternative to gemcitabine with the Folfirinox regimen, with an improvement of overall survival.
  • Biological personalization of cancer treatments is on the road run but the road is still long.
  • [MeSH-major] Medical Oncology / standards. Neoplasms / therapy. Practice Patterns, Physicians' / standards. Societies, Medical / standards
  • [MeSH-minor] Breast Neoplasms / therapy. Digestive System Neoplasms / therapy. Female. Gastrointestinal Stromal Tumors / drug therapy. Genital Neoplasms, Female / drug therapy. Hematologic Neoplasms / therapy. Humans. Lung Neoplasms / drug therapy. Male. Melanoma / drug therapy. Prostatic Neoplasms / drug therapy. Sarcoma / drug therapy. Testicular Neoplasms / drug therapy. Thyroid Neoplasms / drug therapy. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220230.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


25. Yang KC, Chao Y, Luo JC, Kuo JY, Lee RC, Li AF, Li CP: The unusual presentation of gastric adenocarcinoma as a testicular mass: a favorable response to docetaxel and Cisplatin plus oral tegafur/uracil and leucovorin. J Chin Med Assoc; 2010 Feb;73(2):88-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The unusual presentation of gastric adenocarcinoma as a testicular mass: a favorable response to docetaxel and Cisplatin plus oral tegafur/uracil and leucovorin.
  • Testicular metastasis is rare.
  • We present here a 23-year-old gastric cancer patient who first presented with right-side testis swelling and pain.
  • Diagnosis of metastatic adenocarcinoma was made after right-side orchiectomy.
  • Gastric adenocarcinoma with ascites and peritoneal seeding was found after esophagogastroscopy and abdominal computed tomography.
  • The patient received chemotherapy consisting of docetaxel 36 mg/m(2) and cisplatin 30 mg/m(2) on day 1 and day 8, plus oral tegafur/uracil 300 mg/m(2)/day and leucovorin 90 mg/day on day 1 to day 14 in a 21-day cycle, and he had a partial response to the chemotherapy.
  • Metastatic tumors, especially gastric adenocarcinoma, should be considered in the differential diagnosis of patients presenting with testicular mass and they may respond well to chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Testicular Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20171588.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Taxoids; 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin
  •  go-up   go-down


26. Kasai T, Moriyama K, Tsuji M, Uema K, Sakurai N, Fujii Y: Adenocarcinoma arising from a mature cystic teratoma of the testis. Int J Urol; 2003 Sep;10(9):505-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising from a mature cystic teratoma of the testis.
  • A 52-year-old male diagnosed pathologically with metastatic adenocarcinoma of the skin was referred to our department.
  • Histopathological examination revealed a well-differentiated, mucinous adenocarcinoma originating from the gastrointestinal epithelium in a mature cystic teratoma (dermoid cyst) of the testis and metastatic mucinous adenocarcinoma of the skin.
  • We made a diagnosis of teratoma with malignant transformation (TMT) of the testis.
  • Combination chemotherapy with low-dose cisplatin/5'-deoxy-5-fluorouridine (CDDP/5'-DFUR) was initiated, but the patient died 8 months after orchiectomy.
  • At autopsy, similar mucinous adenocarcinoma of the testis and the skin were observed at the metastatic sites.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / secondary. Dermoid Cyst / diagnosis. Skin Neoplasms / secondary. Teratoma / diagnosis. Testicular Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12941133.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


27. Camparo P, Durand X, Avances C, Culine S, Segui B, Rigaud J, Membres du GELU-Groupe d'Etude des Lésions Urologiques, Membres du CCAFU: [Histological features and principles of treating testicle tumors in the elderly subject]. Prog Urol; 2009 Nov;19 Suppl 3:S142-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Particularités histologiques et principes de traitements des tumeurs du testicule du sujet âgé.
  • After the 6th decade, primitive lymphomas are the most frequent tumors of the testis (>30%).
  • Chemotherapy depends on histological subtype.
  • Therapy do not differ from young adults germ cell tumors.
  • The one of metastasis depends on primitive tumor (prostatic or pulmonary adenocarcinoma or melanoma mainly).
  • This particular histological profile must be in mind when considering the appropriate therapeutic approach of testis tumors in elderly.
  • [MeSH-major] Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20123499.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Investigator] Choudat L; Priollet BC; Comperat E; Sibony M; Vassiliu V; Verkarre V; Allory Y; Ferlicot S; Molinié V; Denoux Y; Sautet A; Lesourd A; Trillet M; Petit T; Aillet G; Vieillefond A; Boccon-Gibod L
  •  go-up   go-down


28. El Mesbahi O, Terrier-Lacombe MJ, Rebischung C, Theodore C, Vanel D, Fizazi K: Chemotherapy in patients with teratoma with malignant transformation. Eur Urol; 2007 May;51(5):1306-11; discussion 1311-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in patients with teratoma with malignant transformation.
  • The only published series of patients with TMT treated with chemotherapy comprised 10 patients.
  • Other histological types included adenocarcinoma (n=3) and bronchoalveolar carcinoma (n=1).
  • RESULTS: Primary treatment consisted of surgery alone in 4 patients.
  • The remaining 10 patients received first-line cisplatin-based chemotherapy with resection of residual masses (n=5): 4 patients had a complete response and 5 had a partial response.
  • Overall, 9 patients developed a relapse with a median time of 84 mo (range: 6-168).
  • At relapse, 8 patients received a chemotherapy regimen directed to the non-GCT component.
  • CONCLUSION: To our knowledge, this is by far the largest reported European series of chemotherapy in TMT.
  • Although TMT has a poor prognosis compared to GCT, its management may be improved by adapted chemotherapy associated with surgical resection of residual masses.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / drug therapy. Teratoma / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Humans. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology. Middle Aged. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / pathology. Sarcoma / drug therapy. Sarcoma / pathology. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081678.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


29. Pan CC, Chiang H, Chang YH, Epstein JI: Tubulocystic clear cell adenocarcinoma arising within the prostate. Am J Surg Pathol; 2000 Oct;24(10):1433-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulocystic clear cell adenocarcinoma arising within the prostate.
  • Neoplasms resembling ovarian common epithelial-type tumors, including clear cell adenocarcinomas, rarely occur in the lower urinary tract of men.
  • The clinical as well as the pathologic features are consistent with a clear cell adenocarcinoma as seen in the female genital tract rather than a typical prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Proteins / analysis. Testicular Neoplasms / drug therapy. Testicular Neoplasms / secondary. Testicular Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11023108.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


30. Miyake M, Fujimoto K, Matsushita C, Chihara Y, Tanaka M, Hirayama A, Hirao Y, Uemura H: [Tumor thrombus arising from the superior vena cava and extending into the right atrium in a patient with advanced testicular germ cell tumor]. Hinyokika Kiyo; 2009 Jun;55(6):371-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumor thrombus arising from the superior vena cava and extending into the right atrium in a patient with advanced testicular germ cell tumor].
  • Ultrasonography detected right testicular tumor and computerized tomography scanning revealed a left supraclavicular lymph node mass and bulky retroperitoneal lymph node mass.
  • He initially underwent right high orchiectomy, combination chemotherapy and retroperitoneal lymph node dissection for advanced testicular non-seminomatous germ cell tumor.
  • After complete remission of the lung metastasis with chemotherapy, the serum alpha-fetoprotein began to increase because of superior vena caval thrombus extending into the right atrium.
  • Emergency surgical excision was performed successfully using extracorporeal circulation to prevent pulmonary embolism and the resected specimen pathologically revealed adenocarcinoma interpreted as teratoma malignant transformation.
  • Adjuvant chemotherapy consisting of paclitaxel, ifosfamide and nedaplatin were administered for subsequent slight elevation of serum F-human chorionic gonadotropin beta, resulting in successful normalization again.
  • We report herein an extremely uncommon case of advanced testicular germ cell tumor with development of superior vena caval thrombus extending into the right atrium.
  • [MeSH-major] Heart Atria / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Neoplastic Cells, Circulating / pathology. Testicular Neoplasms / pathology. Thrombosis / pathology. Vena Cava, Superior / pathology

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588874.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  • [Number-of-references] 22
  •  go-up   go-down


31. Laitman CJ: DES exposure and the aging woman: mothers and daughters. Curr Womens Health Rep; 2002 Oct;2(5):390-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DES exposure and the aging woman: mothers and daughters.
  • Diethylstilbestrol (DES), the first orally active artificial estrogen ever developed, was prescribed to several million pregnant women during the 1940s through the 1960s in the mistaken belief that it reduced the risk of miscarriage.
  • In 1971, the US Food and Drug Administration contraindicated its use in pregnancy when DES was associated with the development of vaginal clear cell adenocarcinoma (CCA) in daughters exposed in utero.
  • In daughters whose mothers took DES during pregnancy, the drug has been associated with congenital malformations of the reproductive tract, fertility problems, a possible increased risk of cervical carcinoma in situ, and a presumed lifetime risk of vaginal and cervical CCA.
  • DES mothers have an increased risk of breast cancer (RR = 1.3).
  • DES sons have an increased prevalence of urogenital anomalies, and a possible increased risk of testicular cancer.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Breast Neoplasms / chemically induced. Carcinoma in Situ / chemically induced. Estrogen Replacement Therapy. Female. Genitalia, Female / abnormalities. Humans. Mothers. Nuclear Family. Pregnancy. Pregnancy Complications / prevention & control. Pregnancy, High-Risk. Risk Factors. Uterine Cervical Neoplasms / chemically induced. Vaginal Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12215312.001).
  • [ISSN] 1534-5874
  • [Journal-full-title] Current women's health reports
  • [ISO-abbreviation] Curr Womens Health Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


33. Wai HP, Yau TK, Sze WM, Yeung MW, Hioe F, Lee AW: Metastatic tumour of the tunica vaginalis testis from carcinoma of the stomach. Int J Clin Pract; 2000 Dec;54(10):685-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic tumour of the tunica vaginalis testis from carcinoma of the stomach.
  • A 50-year-old man with advanced inoperable gastric adenocarcinoma and diffuse peritoneal metastasis received six cycles of palliative chemotherapy and responded clinically with weight gain.
  • Two months after the completion of chemotherapy, however, he developed a left hydrocele.
  • Aspiration yielded 70 ml of yellowish hydrocele fluid, which contained metastatic adenocarcinoma cells, consistent with a gastric primary tumour.
  • A diagnosis of malignant hydrocele was made.
  • Two weeks later, he developed a painful recurrent left hydrocele with increasing pain and swelling.
  • No focal lesion was noted in the testis.
  • On microscopic examination, the tunica vaginalis showed reactive mesothelial hyperplasia and extensive lymphatic permeation by poorly differentiated adenocarcinoma, consistent with a gastric primary tumour.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms. Testicular Hydrocele / etiology. Testicular Neoplasms / secondary

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11221287.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Matsuzaki M, Nakano M, Komatsu H, Ohashi K: [Aortic replacement during post chemotherapy retroperitoneal residual tumor resection for nonseminomatous germ cell tumor: a case report]. Hinyokika Kiyo; 2005 Dec;51(12):831-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aortic replacement during post chemotherapy retroperitoneal residual tumor resection for nonseminomatous germ cell tumor: a case report].
  • Abdominal computed tomography revealed large retroperitoneal cystic tumors.
  • His left testis was hard and swollen.
  • Under the diagnosis of testicular tumor and retroperitoneal lymph node metastasis, left radical orchiectomy was performed and the histopathological examination showed mature teratoma.
  • He received three cycles of chemotherapy with bleomycin, etoposide, and cisplatin and we performed retroperitoneal residual tumor resection.
  • Histopathological diagnosis was cystopapillary adenocarcinoma and mature teratoma.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Aorta, Abdominal / surgery. Lymph Node Excision. Lymph Nodes / pathology. Neoplasms, Multiple Primary. Teratoma / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm, Residual / surgery. Orchiectomy. Retroperitoneal Space. Tissue Adhesions

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440734.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


35. Foster RS: Early-stage testis cancer. Curr Treat Options Oncol; 2001 Oct;2(5):413-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage testis cancer.
  • The treatment of low-stage testis cancer (defined as clinical stage I or low-volume clinical stage II disease) varies, depending on whether or not the orchiectomy specimen reveals seminoma or nonseminoma.
  • Treatments for clinical stage I seminoma include radiotherapy to the retroperitoneum, surveillance, or two courses of carboplatin chemotherapy.
  • Until the results of an ongoing randomized study comparing radiotherapy with two courses of carboplatin are known, standard accepted treatments currently include radiotherapy or surveillance.
  • In nonbulky clinical stage II seminoma, therapeutic options include radiotherapy or cisplatin-based chemotherapy.
  • For clinical stage I nonseminoma, equivalent short-term survival rates are obtained with either nerve-sparing retroperitoneal lymph node dissection (RPLND), surveillance, or two courses of BEP (bleomycin, etoposide, and platinum) chemotherapy.
  • However, minimization of toxicity of treatment would argue that the two preferred treatments in clinical stage I nonseminoma are nerve-sparing RPLND or surveillance.
  • Therefore, in each clinical stage of early-stage testis cancer, therapeutic options exist that, based upon current data, are therapeutically equivalent in the short term.
  • Therefore, the ultimate choice of therapy is also dependent upon the short- and long-term toxicity of therapy and the likelihood of late recurrence of disease.
  • [MeSH-major] Testicular Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Epidemiologic Methods. Erectile Dysfunction / prevention & control. Humans. Lymph Node Excision. Lymphatic Metastasis / radiotherapy. Male. Neoplasm Staging. Neuroectodermal Tumors, Primitive / mortality. Neuroectodermal Tumors, Primitive / pathology. Neuroectodermal Tumors, Primitive / therapy. Orchiectomy / adverse effects. Postoperative Complications / prevention & control. Radiation Tolerance. Radiotherapy, Adjuvant. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / radiotherapy. Retroperitoneal Neoplasms / secondary. Risk Factors. Sarcoma / mortality. Sarcoma / pathology. Sarcoma / therapy. Seminoma / mortality. Seminoma / pathology. Seminoma / therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1988 Jun;139(6):1220-4 [2836633.001]
  • [Cites] J Urol. 1996 Feb;155(2):579-86 [8558664.001]
  • [Cites] BJU Int. 1999 Jan;83(1):76-82 [10233456.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1106-13 [8648364.001]
  • [Cites] World J Urol. 1994;12(3):139-42 [7951340.001]
  • [Cites] Eur J Cancer. 1993;29A(14):1931-4 [8280484.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1429-39 [9326912.001]
  • [Cites] J Urol. 1995 Jan;153(1):85-9 [7966799.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):373-9 [8276652.001]
  • [Cites] Semin Urol Oncol. 1996 Feb;14(1):45-53 [8833389.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):362-4 [8275469.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1725-32 [10764433.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1146 [10561173.001]
  • [Cites] Urology. 2000 Jan;55(1):102-6 [10654903.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1762-8 [1403057.001]
  • [Cites] J Urol. 1993 Feb;149(2):237-43 [8381190.001]
  • [Cites] J Urol. 1994 Jan;151(1):72-7; discussion 77-8 [8254836.001]
  • [Cites] J Urol. 1996 Jun;155(6):1943-5 [8618293.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):290-4 [9440755.001]
  • [Cites] J Urol. 1990 Aug;144(2 Pt 1):287-91; discussion 291-2 [2165181.001]
  • (PMID = 12057104.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down






Advertisement